OBJECTIVES: To estimate the impact of the inclusion of dapagliflozin, as an add-on to the standard of care, in the Mexican Health System (MHS) budget, for the treatment of patients with chronic kidney disease (CKD).

METHODS: The budget impact analysis (BIA) considered the actual scenario, where patients with CKD are treated with the standard of care (including: angiotensin-converting enzyme inhibitors, diuretics, statins, and angiotensin II receptor blockers); and a future scenario, considering the addition of dapagliflozin to the standard of care. The penetration rate started with 5% and continue with an annual increase of 5%, for 5 years of time horizon (2022 to 2026). The objective population consisted in adults with CKD in stage 2 – 4. Epidemiological inputs where obtained from epidemiological studies performed in Mexico. The model considered those patients affiliated to a public health institution (IMSS, ISSSTE, PEMEX, SEDENA, SEMAR, INSABI).

RESULTS: The inclusion of dapagliflozin in the MHS lead to a save in the first year of 0.019% of the MHS budget, and a 0.017% save in year 5. Leading to an average annual save of 0.02%. The observed save was consistent between the different institutions included in the analysis. The addition of dapagliflozin to the standard of care reduce significantly the costs associated to adverse events and worsening of the disease.

CONCLUSIONS: The addition of dapagliflozin in the MHS as an add on to the standard of care for the treatment of CKD, might result in saves on the budget of the MHS.